PACE
Prostate Advances in Comparative Evidence
- NCT01584258 ↗
- Active, not recruiting
- Royal Marsden NHS Foundation Trust
- Deep
We haven't built an HCP commentary report on PACE (Prostate Cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Questions raised in the commentary
Automated, Oct 29, 2026. Not an Erudio report: no source links. Not medical advice.
The commentary discusses PACE-A’s comparison of SBRT with prostatectomy and how to place it alongside other prostate radiotherapy trials. Topics include cancer-control measures, patient-reported urinary, sexual and bowel outcomes, treatment choice, and shared decision-making. A speaker questions whether continence was an appropriate co-primary endpoint given the different effects of surgery and radiotherapy. Discussion also addresses the change in primary endpoint, the trial’s shortfall from its planned enrollment, and whether the available evidence can establish equivalence.
Indexed commentary on PACE so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 130 | |
| Podcasts | 5 | |
| YouTube | 4 |
The trial
ClinicalTrials.gov- Official title
- International Randomised Study of Prostatectomy vs Stereotactic Body Radiotherapy (SBRT) and Conventionally Fractionated Radiotherapy vs SBRT for Organ-Confined Prostate Cancer
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Prostate Cancer
- Interventions
- Prostatectomy; Conventionally Fractionated Prostate Radiotherapy; Prostate SBRT
- Arms
- PACE-A: Prostatectomy vs prostate SBRT · Active comparator
- PACE-B: Conventionally Fractionated RT vs Prostate SBRT · Active comparator
- PACE-C: Conventionally Fractionated RT vs Prostate SBRT · Active comparator
- Enrollment
- 2,205
- Primary outcomes
- PACE-B and PACE-C: Freedom from biochemical or clinical failure
- PACE-A: Co-primary patient reported outcomes of urinary incontinence and bowel bother
- Sponsor
- Royal Marsden NHS Foundation Trust with The Institute of Cancer Research, Sutton, Surrey, UK
- Start
- Aug 7, 2012
- Primary completion
- Dec 2025 (estimated)
- Results posted
- No
- Registry record
- NCT01584258 · updated Jan 19, 2024
Publications
linked from the registry- Tree AC, Hinder V, Chan A, Tolan S, Ostler P, van der Voet H, Kancherla K, Loblaw A, Naismith O, Jain S, Martin A, Price D, Brand D, Chu W, Duffton A, Kelly P, O'Neill B, Staffurth J, Sasso G, Pugh J, Manning G, Brown S, Burnett S, Griffin C, Hall E, van As N; PACE Investigators. Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trial. Lancet Oncol. 2025 Jul;26(7):936-947. doi: 10.1016/S1470-2045(25)00205-0. Epub 2025 Jun 12. PubMed 40517778
- Smith RP, Mohammed MA, Beriwal S, Benoit RM. Prostate Brachytherapy With Cs-131: Long-term Results Compared With Published Stereotactic Body Radiotherapy Data. Am J Clin Oncol. 2025 Jan 1;48(1):34-37. doi: 10.1097/COC.0000000000001145. Epub 2024 Oct 17. PubMed 39716881
- van As N, Griffin C, Tree A, Patel J, Ostler P, van der Voet H, Loblaw A, Chu W, Ford D, Tolan S, Jain S, Camilleri P, Kancherla K, Frew J, Chan A, Naismith O, Armstrong J, Staffurth J, Martin A, Dayes I, Wells P, Price D, Williamson E, Pugh J, Manning G, Brown S, Burnett S, Hall E. Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer. N Engl J Med. 2024 Oct 17;391(15):1413-1425. doi: 10.1056/NEJMoa2403365. PubMed 39413377
- Tree AC, Ostler P, van der Voet H, Chu W, Loblaw A, Ford D, Tolan S, Jain S, Martin A, Staffurth J, Armstrong J, Camilleri P, Kancherla K, Frew J, Chan A, Dayes IS, Duffton A, Brand DH, Henderson D, Morrison K, Brown S, Pugh J, Burnett S, Mahmud M, Hinder V, Naismith O, Hall E, van As N; PACE Trial Investigators. Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2022 Oct;23(10):1308-1320. doi: 10.1016/S1470-2045(22)00517-4. Epub 2022 Sep 13. PubMed 36113498
- Brand DH, Tree AC, Ostler P, van der Voet H, Loblaw A, Chu W, Ford D, Tolan S, Jain S, Martin A, Staffurth J, Camilleri P, Kancherla K, Frew J, Chan A, Dayes IS, Henderson D, Brown S, Cruickshank C, Burnett S, Duffton A, Griffin C, Hinder V, Morrison K, Naismith O, Hall E, van As N; PACE Trial Investigators. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. Lancet Oncol. 2019 Nov;20(11):1531-1543. doi: 10.1016/S1470-2045(19)30569-8. Epub 2019 Sep 17. PubMed 31540791